Mylan (NASDAQ:MYL) has been given a $43.00 price target by stock analysts at Wells Fargo & Co in a note issued to investors on Thursday. The firm currently has a “hold” rating on the stock. Wells Fargo & Co’s target price would indicate a potential downside of 7.98% from the company’s current price.
MYL has been the topic of several other reports. Citigroup set a $42.00 price target on shares of Mylan and gave the company a “buy” rating in a report on Wednesday, October 4th. Zacks Investment Research raised shares of Mylan from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Guggenheim started coverage on shares of Mylan in a report on Tuesday, December 12th. They set a “buy” rating and a $59.00 target price on the stock. Instinet reaffirmed a “buy” rating and set a $37.00 target price on shares of Mylan in a report on Thursday, October 5th. Finally, BTIG Research raised their target price on shares of Mylan from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Mylan has a consensus rating of “Buy” and a consensus price target of $44.19.
Mylan (MYL) traded up $0.22 during trading on Thursday, reaching $46.73. 7,890,000 shares of the company’s stock traded hands, compared to its average volume of 6,680,000. The company has a market cap of $25,070.00, a PE ratio of 28.15, a P/E/G ratio of 1.48 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46. Mylan has a 52-week low of $29.39 and a 52-week high of $47.25.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). The company had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. The firm’s revenue was down 2.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.38 earnings per share. equities analysts forecast that Mylan will post 4.55 EPS for the current year.
In related news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.69% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Meeder Asset Management Inc. boosted its position in Mylan by 76.9% in the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after buying an additional 1,475 shares in the last quarter. BT Investment Management Ltd acquired a new stake in Mylan in the third quarter valued at approximately $142,000. Doliver Capital Advisors LP acquired a new stake in Mylan in the second quarter valued at approximately $201,000. Charter Trust Co. acquired a new stake in Mylan in the fourth quarter valued at approximately $226,000. Finally, Parametrica Management Ltd acquired a new stake in Mylan in the third quarter valued at approximately $224,000. Hedge funds and other institutional investors own 74.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/21/mylan-myl-given-a-43-00-price-target-at-wells-fargo-co.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.